Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for priority review the supplemental biologics license application for ...

Who would've thought that a child's toy would've been the inspiration for the name of the greatest spectacle in professional sports? It's safe to say that not even Lamar Hunt, the man who is ...

WASHINGTON ‒ Federal employees at multiple departments were instructed Friday to remove personal pronouns from their email signatures by 5 p.m. as agencies rushed to carry out President Donald ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, 2025. The Zacks Consensus Estimate for fourth-quarter revenues is pegged ...

Khaleda Rahman is Newsweek's National Correspondent based in London, UK. Her focus is reporting on abortion rights, race, education, sexual abuse and capital punishment. Khaleda joined Newsweek in ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,030.00. The company’s shares closed yesterday at $686.33.

"We had Caitlin Clark today," Hill told Fortune. "... We're working on her signature shoe that will launch, and we're working on her logo and that design." Hill did not say when Clark's shoe or ...